Anticholestatic mechanisms of Ursodeoxycholic acid (cas 128-13-2) in lipopolysaccharide-induced cholestasis
-
Add time:09/10/2019 Source:sciencedirect.com
Lipopolysaccharide (LPS) from Gram (-) bacteria induces inflammatory cholestasis by impairing the expression/localization of transporters involved in bile formation (e.g., Bsep, Mrp2). Therapeutic options for this disease are lacking. Ursodeoxycholic acid (cas 128-13-2) (UDCA) is the first choice therapy in cholestasis, but its anticholestatic efficacy in this hepatopathy remains to be evaluated. To asses it, male Wistar rats received UDCA for 5 days (25 mg/Kg/day, i.p.) with or without LPS, administered at 8 a.m. of the last 2 days (4 mg/Kg/day, i.p.), plus half of this dose at 8 p.m. of the last day. Then, plasma alkaline phosphatase (ALP), bile flow, basal and taurocholate-stimulated bile acid output, total glutathione output, and total/plasma membrane liver protein expression of Bsep and Mrp2 by confocal microscopy were assessed. mRNA levels of both transporters were assessed by Real-Time PCR. Plasma pro-inflammatory cytokines (IL-6 and TNF-α) were measured by ELISA. Our results showed that UDCA attenuated LPS-induced ALP plasma release and the impairment in the excretion of the Bsep substrate, taurocholate. This was associated with an improved Bsep expression at both mRNA and protein levels, and by an improved localization of Bsep in plasma membrane. UDCA failed to reduce the increase in plasma pro-inflammatory cytokines induced by LPS and Mrp2 expression/function. In conclusion, UDCA protects the hepatocyte against the damaging effect of bile acids accumulated by the LPS-induced secretory failure. This involved an enhanced synthesis of Bsep and an improved membrane stability of the newly synthesized transporters.
We also recommend Trading Suppliers and Manufacturers of Ursodeoxycholic acid (cas 128-13-2). Pls Click Website Link as below: cas 128-13-2 suppliers
Prev:Ursodeoxycholic acid (cas 128-13-2) and cancer: From chemoprevention to chemotherapy
Next:Original articleAdherence to Ursodeoxycholic acid (cas 128-13-2) therapy in patients with cholestatic and autoimmune liver disease) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research ArticleUrsodeoxycholic acid (cas 128-13-2) therapy and liver transplant-free survival in patients with primary biliary cholangitis09/28/2019
- Original articleEffect of oral Ursodeoxycholic acid (cas 128-13-2) on cholelithiasis following laparoscopic sleeve gastrectomy for morbid obesity10/01/2019
- Ursodeoxycholic acid (cas 128-13-2) is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH09/27/2019
- Enzymatic routes for the synthesis of Ursodeoxycholic acid (cas 128-13-2)09/26/2019
- ArticlesUrsodeoxycholic acid (cas 128-13-2) versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial09/25/2019
- Original articleAdherence to Ursodeoxycholic acid (cas 128-13-2) therapy in patients with cholestatic and autoimmune liver disease09/24/2019
- Ursodeoxycholic acid (cas 128-13-2) and cancer: From chemoprevention to chemotherapy09/09/2019
-
Health and Chemical more >